OncoImmunology

Tumor immunology deals with the natural or therapy-induced recognition of cancers, as well as with the intricate interplay between oncogenesis, inflammation and immunosurveillance. We now create a new, high-profile journal, OncoImmunology, that specifically deals with tumor immunology. Recent progress has allowed for the first clinical demonstration (and FDA approval) of anticancer immunotherapies. There is also an ever growing suspicion that - unexpectedly - many of the currently used chemotherapeutic agents depend in their efficacy on the active contribution of immune effectors. To use a drastic metaphor, oncologists who applied successful chemotherapeutic (or radiotherapeutic) regimens have taken advantage of the immune system's capacity to recognize tumor-specific or tumor-associated antigens and to control cancer (stem) cell growth, without being aware of the invisible helping hands. As a result, immunological biomarkers are becoming ever more important to determine the prognosis of cancers and to predict the efficacy of chemotherapies. There is also a strong rationale in favor of combining conventional anticancer therapies with immunotherapies.

 

  • Tumour Immunology
  • Cancer Immunotherapy

Related Conference of OncoImmunology

July 29-30 2019

6th International Conference on Parasitology & Microbiology

Amsterdam, Netherlands
July 29-30, 2019

11th Global Summit on Immunology and Cell Biology

Sydney, Australia
November 12-13, 2019

13th International Congress on Autoimmunity

Brisbane, Australia
November 14-15, 2019

International Conference on Vaccines and Immune Response

Istanbul, Turkey
November 14-15, 2019

Annual Congress on Antibiotics and Antimicrobial Resistance

Geneva, Switzerland
November 21-22, 2019

World Conference on Vaccine and Immunology

Dubai, UAE

OncoImmunology Conference Speakers

Recommended Sessions

Related Journals

Are you interested in